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Abstract
Introduction: The purpose of this study was to examine the diagnostic performance of autoantibodies against
citrullinated peptides/proteins (ACPA) and to determine the prevalence of HLA-DRB1 shared epitope alleles (SE) in
African patients with rheumatoid arthritis (RA).
Methods: Serum levels of anti-cyclic citrullinated peptides antibodies (anti-CCP2, anti-CCP3), IgM and IgA
rheumatoid factors (RF) were measured by enzyme-linked immunosorbent assay in the serum of 56 consecutive RA
patients regularly followed in the Rheumatology Unit of the School of Medicine, University of Yaoundé, Yaoundé,
Cameroon. Genotyping of HLA-DRB1 alleles was performed by polymerase chain reaction and hybridization with
sequence-specific oligonucleotide probes on microbeads arrays. Fifty-one patients with other inflammatory
rheumatic diseases and 50 healthy individuals were included as controls.
Results: An anti-CCP2 assay showed the best diagnosis sensitivity (82%) and specificity (98%) with high positive
predictive (PPV) (96%) and negative predictive values (NPV) (91%). Thirty percent of RA patients were carrying at
least one copy of the HLA-DRB1 shared epitope (SE) compared to 10% and 14% of patients with other
inflammatory rheumatic diseases and healthy individuals, respectively. The presence of the SE was associated with
the production of ACPA.
Conclusions: Anti-CCP2 antibodies are useful markers of RA in African patients. In this cohort, the prevalence of
the SE is higher in RA patients than in controls but lower than that reported in patient cohorts of European
ancestry. The discrepancy between the high prevalence of ACPA-positive patients and the relatively low number of
SE-positive cases suggest that, in addition to SE, other genetic factors control the development of ACPA in African
RA patients.
Introduction
Rheumatoid arthritis (RA) is characterized by inflamma-
tion of the synovial membrane of diarthrodial joints
leading to tissue destruction and severe disability. The
cause of RA is unknown but genetic susceptibility and
environmental factors appear to be involved. RA is the
most frequent systemic autoimmune inflammatory dis-
ease with a prevalence of approximately 0.5 to 1% in
populations of European ancestry. However, it appears
to have a relatively lower prevalence among African
populations, particularly those living in rural settings
[1-3].
Two important autoantibody systems have been
described in RA, including rheumatoid factors (RF)
directed to the Fc fragment of IgG and autoantibodies
against citrullinated peptides/proteins (ACPA). RFs are
well-known autoantibodies associated with RA and are
present in approximately 70 to 80% of RA patients, but
because they are also detected in patients with other
autoimmune diseases as well as in chronic infections
and in lymphoma or other tumoral processes, they have
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limited specificity. ACPA such as anti-cyclic citrullinated
peptides (anti-CCP) are directed to antigens that contain
arginyl converted to citrullyl residues by peptidylarginyl
deiminase enzymes [4,5]. Several studies have shown
that these antibodies are present in 60% to 80% of Cau-
casian RA patients with a high specificity of more than
95% [6]. However, there are no data regarding the pre-
sence of these antibodies in African patients with RA.
The genetic component of RA has been determined
with heritability estimates of 50% to 60% [7]. The major
susceptibility loci associated with susceptibility to RA
were identified approximately 30 years ago and consist
of the human leukocyte antigen (HLA) class II mole-
cules. There is extensive evidence that some HLA-DRB1
alleles, including HLA-DRB1*0101, HLA-DRB1*0102,
HLA-DRB1*0401, HLA-DRB1*0404, HLA-DRB1*0405,
HLA-DRB1*0408, HLA-DRB1*0410, HLA-DRB1*1001,
HLA-DRB1*1402 are associated with susceptibility to
RA. These alleles share a common amino acid sequence
(QKRAA, QRRAA, or RRRAA), also termed shared epi-
tope (SE), located at positions 70 to 74 within the third
hypervariable region of DRB1, forming part of the anti-
gen-binding site. The shared epitope accounts for at
least 30% of the total genetic susceptibility [8]. In addi-
tion, the associations between the SE and other genetic
markers including PTPN22, CTLA4, CD40 genes, the
TRAF1/C5 region and SNPs between OLIG3 and
TNFAIP3 genes, and anti-CCP positivity have been
reported in different populations (reviewed in [9]).
The objective of this study was to examine the preva-
lence of ACPA detected by anti-CCP2 and anti-CCP3
enzyme-linked immunosorbent assays (ELISAs), and
that of HLA-DRB1 alleles in African RA patients in
order to examine first the diagnostic performance of
these serological tests as compared to RF, and then the




This study was carried out on 56 RA patients recruited
consecutively from the outpatient Rheumatology Clinic
of Yaoundé Central Hospital in Cameroon. These RA
patients fulfilled the American College of Rheumatology
1987 criteria for RA [10]. Fifty-one patients (20 females)
with other rheumatic conditions and ages ranging from
16 to 65 (median 28), and 50 healthy individuals (33
females) with ages ranging from 22 to 55 (median 34)
were included as controls. Patients with other inflamma-
tory rheumatic conditions were consecutively recruited
from the same outpatient clinic, while healthy controls
were recruited among medical students and hospital
workers in Yaoundé. Patients with RA were treated with
disease modifying antirheumatic drugs (DMARDs),
including methotrexate, hydroxychloroquine, sulphasala-
zine, leflunomide, combinations of methotrexate, hydro-
xychloroqine and sulphasalazine and/or oral prednisone.
RA patients were assessed for demographic characteris-
tics, disease duration, duration of morning stiffness, pain
by visual analogue scale, number of tender joints, num-
ber of swollen joints, the presence or absence of
nodules, extra-articular manifestations, and co-morbid-
ities. The disease activity score (DAS28) was calculated
as previously described [11]. Hand radiographs were
obtained for each RA patient. Approval of the Camer-
oon National Ethical Committee was obtained prior to
the study and an informed consent was obtained from
all patients and controls included in this study.
IgM and IgA RF determinations by enzyme immunoassays
Commercially available ELISA kits, purchased from
Inova Diagnostics (Ruwag, Zurich, Switzerland), were
used to detect IgM and IgA RF. The assays and calcula-
tions were performed according to the manufacturer’s
instruction. Each kit included its own RF standard and
the results were calculated as arbitrary units/ml. The
diagnostic performance of these kits has been previously
evaluated in a Swiss population of RA patients and con-
trols [12].
Anti-cyclic Citrullinated Peptide antibody determination
by enzyme immunoassay
The ELISA kits detecting the IgG anti-CCP2 antibodies
(Immunoscan RA: regular, second generation of CCP
antigen), were purchased from Euro-Diagnostica
(Pharma Consulting, Burgdorf, Switzerland), and those
detecting the IgG anti-CCP3 (Quanta Lite CCP3: third
generation of CCP antigen), were purchased from Inova
Diagnostics (Ruwag, Zurich, Switzerland). The assays
and calculations were performed according to the man-
ufacturers’ protocols. Each manufacturer uses its own
anti-CCP calibrator and the results were calculated as
arbitrary units/ml. In addition, to avoid false positive
results for anti-CCP2 antibody determination, reactivity
to non-citrullinated peptides containing arginyl instead
of citrullyl residues was also tested. Diagnosis sensitivity
and specificity of anti-CCP2 antibody determination
have been previously determined in our laboratory in
Swiss and in French patients with RA and in controls
[13,14]. The sensitivity and specificity of anti-CCP3
were compared to those of anti-CCP2 in two studies on
different populations [15,16].
HLA-DRB1 genotyping
Genomic DNA was extracted from 350 μl-aliquots of
frozen blood samples by using the GenoM6 magnetic
bead-based workstation. HLA-DRB1 generic typing
was performed by PCR-SSOP (sequence-specific
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oligonucleotide probes) reverse hybridization using the
Luminex technology after locus-specific exon 2 amplifi-
cation. The method is based on fluorescent microbeads
coated with oligonucleotide probes specific for the poly-
morphic positions of DRB1 exon 2 sequences (LabType
RSSO2B HD, OneLambda). Automated reading (Labs-
can TM100, Luminex, Austin, Texas USA)) and inter-
pretation led to HLA-DRB1 high resolution (four-digit)
typing as previously described [17].
Statistical Analysis
The disease characteristics of RA patients (Table 1) were
described using standard non-parametric statistics (med-
ian and interquartile ranges) for continuous outcomes
and percentages for dichotomous outcomes.
The diagnostic performances and cut offs of all the
serological assays used in this study have been initially
validated in Caucasians. Thus, we decided to identify
the most discriminant cut-off values of the different
tests for this particular population, which were opera-
tionally defined as the cut-off values leading to the high-
est percentage of correctly classified patients. The most
discriminant cut-offs to be considered as positive were
with values ≥ 22 units/ml for IgM RF, ≥ 1 unit/ml for
IgA RF, ≥ 32 units/ml for anti-CCP2, ≥ 17 units/ml for
anti-CCP3, respectively. Using these established cut-offs,
we computed the sensitivity, the specificity, the positive
predictive value (PPV) and the negative predictive value
(NPV) of the various biologic tests in this population.
We used the area under the curve (AUC) of the receiver
operating curves (ROC) to compare the diagnostic per-
formance of the various biologic tests in this population.
Sensitivity and specificity were compared using the
exact McNemar’s probability test.
Finally, we examined the agreement or correlation
between these biomarkers using a kappa statistic. We
then examined which of these tests provided indepen-
dent information for the diagnosis of RA. We first per-
formed simple stratified analyses (patients stratified
according to their genetic SE status) and then performed
a multivariate logistic regression model, where the diag-
nosis of RA was the dependent variable and the various
tests the independent variables. All statistical tests were
two-sided and at the 0.05 significance level. The statisti-
cal analysis was performed with STATA v. 9.1.
Results
This study included all the RA patients followed at the
University Hospital outpatient clinic of Yaoundé,
Cameroon. The clinical characteristics of these 56
patients are described in Table 1. Most of them were
female with established disease (more than two years).
All of them had either moderate or active disease
according to DAS28 levels and 44% had radiographic
signs of joint erosions on hand X-rays. Ninety-one per-
cent of patients were on DMARDs and the vast majority
of them were on methotrexate (77%). Seven out of 56
patients received a combination of DMARDs but none
of them were on biologic therapy as these drugs are not
available in Cameroon. Fifty-one control patients with
inflammatory rheumatic diseases were recruited from
the same outpatient clinic and had disease duration ran-
ging from 1 to 10 years (median 3). The different diag-
nosis included 18 unclassified oligoarthritis (some cases
with probable reactive arthritis), thirteen patients with
ankylosing spondylitis, three psoriatic arthritis, nine sys-
temic lupus erythematosus, three oligoarthritis in HIV-
positive patients, three adult Still’s disease, one systemic
sclerosis, and one adult with juvenile idiopathic arthritis.
The serological characteristics of the three tested
groups and the sensitivity, specificity, PPV and NPV,
and the AUC of the ROC of the different serological
tests for the diagnosis of RA are described in Table 2.
IgM RF and IgA RF were detected in 77% and 84% of
RA patients with a specificity of 93% and 92%, respec-
tively. Anti-CCP2 antibodies were present in 82% of
RA patients and detected in only one subject (2%)
from either of the control groups. Thus, anti-CCP2
antibodies had a high NPV and PPV and a high diag-
nostic performance as assessed by the AUC of the
ROC (0.91, 95% CI 0.85 to 0.96). Of note, we did not
detect any reactivity to control non-citrullinated pep-
tides containing arginyl instead of citrullyl residues.
Anti-CCP3 antibodies were less sensitive and specific
than anti-CCP2 antibodies, but the difference was not
statistically significant.
Table 1 Baseline characteristics of RA patients
Age (yrs) 53.5 (39 to 61.5)
Female sex (%) 95
Disease duration (yrs) 3 (2 to 6)
Erosions (%) 44
Subcutanous nodules (%) 7
DAS28 4.72 (3.8 to 6.4)
Morning stiffness (minutes) 30 (10 to 60)
VAS-pain (0 to10) 5 (3 to 7)
CRP (mg/L) 12 (6 to 35)
Tobacco, N (%) 1 (2)
Prednisone, N (%) 51 (91)
Dose (mg/day) 10
Methotrexate, N (%) 43 (77)
Dose (mg/day) 10
Sulfasalazine, N (%) 7 (12)
Azathioprine, N (%) 2 (5)
Leflunomide, N (%) 2 (5)
D-penicillamine, N (%) 1 (2)
Continuous values are presented as median (interquartile range 25 to 75);
CRP, C-reactive protein; DAS, disease activity score; VAS, visual analogue score
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Of the 157 DRB1-typed samples a total of 21 alleles were
identified. The following two allele groups were not
resolved because the differences are located in the third
exon: DRB1*1201/06/10 and DRB1*1401/54. The allele
frequency distribution in the healthy controls (n = 50) was
very similar to that reported in a sample of Cameroonese
students [18]. The seven most frequent alleles
(DRB1*0301, *0302, *0804, *1101, *1301, *1302, and *1503)
accounted for 77.5% of the alleles in our control group, as
compared to 71.5% in the published cohort [18]. In our
study group the SE was represented by only four alleles:
DRB1*0101, *0102, *0405, and *1001 (Table 3). One copy
of the SE was detected in 17 RA patients (30%), 7 patients
with other rheumatic diseases (14%), and 5 healthy indivi-
duals (10%) (P = 0.029, Chi2 test). Two copies were
detected in two RA patients but in none of the controls
(Table 3). HLA-DRB1*0102, *1001, *0405 were the most
frequent SE-positive alleles in RA patients and in control
patients.
We examined the association between the presence of
the SE and that of ACPA. We observed a positive trend
between the presence of SE and anti-CCP2 and anti-CCP3
(Table 4). In addition, in a univariate logistic regression,
the association between the SE and the diagnosis of RA
disappeared when the presence of ACPA was taken into
account in the model, thus further supporting the relation-
ship between SE and ACPA-positive RA.
All the immunological tests were significantly corre-
lated to each other and the agreement ranged between
70% and 90% (kappa test). In a multivariate logistic
regression analysis, IgM RF, IgA RF, anti-CCP2, and
anti-CCP3 were independently associated with RA,
which suggests that all these autoantibodies provide
complementary information for the diagnosis of RA.
Discussion
Our study of African RA patients confirmed previous
studies in patients of European ancestry showing that
anti-CCP2 and anti-CCP3 antibodies exhibit high diag-
nostic specificity for RA with anti-CCP2 antibodies hav-
ing the highest PPV and NPV. However, the number of
patients and controls included in our study limits the
interpretation of these results, and future studies includ-
ing a larger number of individuals should be carried out
in the African population to confirm these findings.
Interestingly, a recent report including Dutch patients
with undifferentiated arthritis and comparing anti-
CCP2, anti-CCP3, anti-citrullinated vimentin, and RF
showed that anti-CCP2 tended to achieve the highest
PPV for RA development [19].
Table 2 Serological and immunogenetic characteristics in RA patients, controls with inflammatory rheumatic diseases,
and healthy individuals
Laboratory values RA IRD (n = 56) HI (n = 51) Sensitivity (n = 50) Specificity PPV NPV AUC (ROC) (95%) CI
RF IgM (%) 43 3 (6) 4 (8) 77 93 86 88 0.85 (0.79 to 0.91)
RF IgA (%) 47 8 (16) 0 (0) 84 92 85 91 0.88 (0.82 to 0.94)
Anti-CCP2 (%) 46 1 (2) 1 (2) 82 98 96 91 0.90 (0.85 to 0.96)
Anti-CCP3 (%) 43 4 (8) 1 (2) 77 95 90 88 0.86 (0.80 to 0.92)
SE 1 or 2 copies (%) 17 7 (14) 5 (10) 30 88 59 70 0.59 (0.52 to 0.66)
- SE 1 copy (%) 15 7 (14) 5 (10) 27 88 56 68 0.57 (0.51 to 0.64)
- SE 2 copies (%) 2 0 (0) 0 (0) 4 100 100 65 0.52 (0.49 to 0.54)
Anti-CCP, anti-cyclic citrullinated peptides; AUC, area under the curve in the ROC analysis; HI, healthy individuals; IRD, inflammatory rheumatic diseases; RA,
rheumatoid arthritis; RF, rheumatoid factor; Sensitivity, the percentage of RA patients who would be identified as having RA by the laboratory tests (positive test
results); Specificity, the percentage of control patients (IRD and HI together) who would be identified as not having RA by the laboratory tests (negative test
results); PPV, positive predictive value or the proportion of RA patients with positive test results who are correctly diagnosed as having RA; NPV, negative
predictive value or the proportion of control patients with negative test results who are correctly diagnosed as not having RA; SE, shared epitope








0101 1 0 0
0102 5 4 3
1001 5 1 2
0405 4 2 0
0102/0405 1 0 0
0102/1001 1 0 0
Total: 17 7 5
HI, healthy individuals; IRD, inflammatory rheumatic diseases; RA, rheumatoid
arthritis
Table 4 Role of the shared epitope as predictor of the
presence of ACPA and RF in RA patients
SE (1 or 2 copies) IgM RF IgA RF anti-CCP2 anti-CCP3
pos neg pos neg pos neg pos neg
0 29 10 32 7 30 9 30 9
1 14 3 15 2 16 1 16 1
P = 0.73 P = 0.71 P = 0.25 P = 0.12
Patients with RA were separated according to the presence (1) or absence (0)
of one or two copies of the shared epitope (SE) and the presence (pos) or
absence (neg) of IgM rheumatoid factor (RF), IgA RF, anti-cyclic citrullinated
peptides (CCP)2, anti-CCP3. The statistical analysis was performed by using
Fisher’s exact
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IgM RF is the only serological marker for RA cur-
rently available in Cameroon. The validation of the
assay for the Cameroonese population led to a marked
increase of cut-off values, as compared to those recom-
mended by the vendor, in order to improve the specifi-
city of the test. The presence of elevated background
levels of IgM RF in African controls (16% of IgM RF-
positive healthy controls when using the recommended
cut-off values) is probably caused by non-specific activa-
tion of the immune system by different infectious and
parasitic diseases. Interestingly, the results of ACPA
tests, in particular anti-CCP2 positivity, were not influ-
enced in a similar manner as IgM RF.
Only a few studies have been conducted to determine
the association between HLA-DRB1 and RA in Africa.
These studies included a limited number of patients and
mainly referred to HLA-DR antigens detected by serolo-
gical typing or by low resolution DNA typing. One
study on Zimbabweans showed a higher prevalence of
HLA-DR4 in RA patients, [20]. A study performed in
Senegal showed that the relative risk (RR) of developing
RA was significantly associated with HLA-DR10 (RR
32), but not HLA-DR4 (RR 0.8) [21]. The frequency of
SE-containing HLA-DRB1 alleles was 25.2% in African
Americans with RA as compared to 13.6% in healthy
subjects. Thus, the SE was significantly associated with
susceptibility to RA, but the percentage of SE positivity
was globally lower than that reported in RA patients of
European ancestry, which ranges between 50 to 70%
[22,23]. The frequency of HLA-DRB1*0401, 0404, 0405,
and 1001 alleles were higher among African American
RA patients than in healthy controls. Of note, a higher
level of European admixture was associated with a
higher likelihood of carrying the SE among African
Americans. More specifically, HLA-DRB1*0401 but not
the other alleles encoding the SE, was significantly asso-
ciated with the presence of European ancestry [24]. In
another study, HLA-DRB1*0102 and HLA-DRB1*0405
were significantly more frequent among African Ameri-
can RA than European RA patients with odds ratio
(OR) of 8.66 and 2.75, respectively. HLA-DRB1*1001
tended also to be more frequent in African American
RA than European RA patients (OR 2.11). In contrast,
an opposite result was found regarding HLA-
DRB1*0401 with an odds ratio of 0.15 [25]. Thus, our
results as well as recent reports on African American
patients indicate that, although the presence of the SE is
associated with RA, its frequency is much lower than
that observed in patients of European ancestry, with also
a distinct SE allele profile characterized in particular by
a lower HLA-DRB1*0401 frequency.
RA is a clinically heterogeneous disease and there has
been some speculation recently that it may comprise at
least two distinct subgroups characterized by the
presence/absence of ACPA. For example, the carriage of
the SE appears particularly confined to anti-CCP posi-
tive RA cases [26,27]. In addition, a significant associa-
tion between SE and the presence of anti-CCP2
antibodies was demonstrated in African American RA
patients [24]. In our study, there was also an association
between ACPA and SE. However, this association was
relatively weak, probably due to the limited number of
patients included in our study. The fact that ACPA are
present in a similar percentage of African patients as
previously reported in European patients despite a
major difference in the proportion of SE-positive
patients, suggests that other non-HLA genetic factors
contribute to the development of RA and of these auto-
antibodies in African RA patients. Of note, an African
specific allele of CTLA4 has recently been shown to
confer protection against RA in African Americans [28].
Tobacco use was shown to be associated with the
development of the disease, in particular in anti-CCP2-
positive, SE-positive RA patients [26]. In one study, the
conjunction of tobacco use and HLA-DRB1*0101 or
*0102 was the strongest factor for the development of
these antibodies [29]. With the exception of one case,
none of our patients smoked, which is in line with gen-
eral living habits of African women. This finding sug-
gests that other environmental factor may be involved
in the development of RA.
To our knowledge this study is the first report on
combined HLA-DRB1 SE and ACPA status in an Afri-
can patient cohort without known European admixture.
It has, however, limitations due to the limited number
of patients and controls included. In addition, the
patient population is highly selected as we had only
access to outpatients followed in a university hospital,
representing patients from an urban setting with moder-
ate to severe disease. However, the Rheumatology Unit
is the only specialized center available for the population
of Yaoundé and its suburbs and we reduce this bias by
including all the RA patients attending the clinic with-
out any further selection.
Conclusions
Our study showed that anti-CCP2 antibodies are sensi-
tive and specific diagnostic markers of RA also in Afri-
can patients. The discrepancy between the high
prevalence of ACPA-positive patients and the relatively
low number of SE-positive cases as well as the relative
lack of tobacco smokers suggest that other genetic and
environmental factors control the development of
ACPA in African RA patients.
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